A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands

Pfizer87 enrolled

Overview

The purpose of this study is to describe the efficacy and safety of bosutinib in patients with chronic myeloid leukaemia used in a real world setting

Study Type

OBSERVATIONAL

Enrollment

Conditions

Chronic Myeloid Leukaemia

Interventions

BosutinibDRUG

Bosutinib 100mg film-coated tablets; Bosutinib 500mg film-coated tablets Dosage as prescribed at treating institution; (observational study)

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosis of Ph+ CML aged ≥18 years at bosutinib initiation. * Prescribed bosutinib (irrespective of the phase of their disease) EITHER in normal clinical practice since it received marketing authorisation (27th March 2013) by the EMA11 OR via the compassionate use programme prior to marketing authorization. * Where required, evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. Exclusion Criteria: * Prescribed bosutinib as part of an interventional clinical trial programme. * Initiated on bosutinib less than 3 months prior to data collection taking place.

Locations (3)

Royal Liverpool Hospital

Liverpool, Merseyside, United Kingdom

Hammersmith Hospital

London, United Kingdom

Nottingham University Hospital

Nottingham, United Kingdom

Outcomes

Primary Outcomes

Percentage of Participants With Cumulative Complete Haematological Response (CHR)

Haematological response used blood sample of the participants to evaluate response to treatment for CML. Based on the European LeukemiaNet (ELN) 2013 definition: CHR is defined as platelet count less than (\<) 450\*10\^9 per liter, white blood cells count \<10\*10\^9 per liter, no immature granulocytes and \<5 percent (%) basophils on differential and a non-palpable spleen.

Time frame: Baseline up to 5.5 years

Percentage of Participants With Cumulative Partial Haematological Response (PHR)

Haematological response used blood sample of the participants to evaluate response to treatment for CML.

Time frame: Baseline up to 5.5 years

Percentage of Participants With Cumulative Complete Cytogenetic Response (CCyR)

Cytogenetic response (CyR) used bone marrow/blood sample of the participants to evaluate response to treatment for CML. Based on the ELN 2013 definition: CyR was measured by chromosome banding analysis (CBA) or fluorescence in situ hybridisation (FISH). CCyR was indicated by absence of Philadelphia chromosome positive (Ph+) cells metaphases from FISH of blood interphase cell nuclei.

Time frame: Baseline up to 5.5 years

Percentage of Participants With Cumulative Minor Cytogenetic Response (MCyR)

CyR used bone marrow/blood sample of the participants to evaluate response to treatment for CML. Based on the ELN 2013 definition: CyR was measured by CBA or FISH. MCyR was indicated by presence of 36-65% Ph+ cells from CBA of bone marrow metaphases.

Time frame: Baseline up to 5.5 years

Percentage of Participants With Cumulative Minimal Cytogenetic Response (mCyR)

CyR used bone marrow/blood sample of the participants to evaluate response to treatment for CML. Based on the ELN 2013 definition: CyR was measured by CBA or FISH. mCyR was indicated by presence of 66-95% Ph+ cells from CBA of bone marrow metaphases.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Percentage of Participants With Cumulative Complete Molecular Response 4.0 (MR4.0)

Molecular response used blood sample of the participants to evaluate response to treatment for CML. Based on the ELN 2013 definition: Molecular response used breakpoint cluster region/Abelson (BCR-ABL1) transcript measured by real time quantitative polymerase chain reaction (RT-Q-PCR). Evaluation was expressed as percentage of ratio of BCR-ABL1 transcripts to ABL1 transcripts according to the international scale (IS) or the ratio of BCR/ABL1 transcripts to other internationally recognized control transcripts levels. MR4.0 was defined and recorded as detectable disease with \<0.01% BCR-ABL1 transcripts on IS or undetectable disease in cDNA with greater than (\>) 10,000 ABL1 transcripts in the same volume of cDNA used to test for BCR-ABL1 transcripts.

Time frame: Baseline up to 5.5 years

Percentage of Participants With Cumulative Complete Molecular Response 4.5 (MR4.5)

Molecular response used blood sample of the participants to evaluate response to treatment for CML. Based on the ELN 2013 definition: Molecular response used breakpoint cluster region/Abelson (BCR-ABL1) transcript measured by real time quantitative polymerase chain reaction (RT-Q-PCR). Evaluation was expressed as percentage of ratio of BCR-ABL1 transcripts to ABL1 transcripts according to the international scale (IS) or the ratio of BCR/ABL1 transcripts to other internationally recognized control transcripts levels. MR4.5 was defined and recorded as detectable disease with \<0.0032% BCR-ABL1 transcripts on IS or undetectable disease in cDNA with \>32,000 ABL1 transcripts in the same volume of cDNA used to test for BCR-ABL1 transcripts.

Time frame: Baseline up to 5.5 years

Secondary Outcomes

Percentage of Participants With Treatment Related Adverse Events (AEs)

Treatment-related AE was any untoward medical occurrence attributed to Bosutinib in a participant who received Bosutinib. Relatedness to Bosutinib was assessed by the investigator.

Time frame: Baseline up to 5.5 years

Percentage of Participants With Treatment Related Adverse Events (AEs) Greater Than or Equal to Grade 3

Treatment-related AE was any untoward medical occurrence attributed to Bosutinib in a participant who received Bosutinib. AE was assessed according to maximum severity grading based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Grade 1 =mild; Grade 2 =moderate; within normal limits, Grade 3 =severe or medically significant but not immediately life-threatening; Grade 4 =life-threatening or disabling; urgent intervention indicated; Grade 5 =death.

Time frame: Baseline up to 5.5 years

Progression-free Survival (PFS)

PFS was defined as the duration between initiation of Bosutinib therapy and date of progression estimated by the treating physician or death of participant (all causes combined). Progression was defined as change from chronic phase of CML (CP-CML) to accelerated phase of CML (AP-CML) or to blast crisis of CML (BC-CML). CP-CML is frequently asymptomatic and diagnosed with \<10% blasts. Based on the ELN 2013 definition: AP-CML was defined by the presence of blast cells between 15-29% or blast cells plus promyelocytes \>30%, with blasts \<30% in blood or bone marrow, platelet count \<100\*10\^9 or clonal chromosome abnormalities in Ph+ cells. BC-CML was defined as blasts in blood or bone marrow \>=30%, extramedullary blast proliferation (excluding spleen), large foci or clusters of blasts in bone marrow biopsy. Participants who were alive at the date of last assessment were censored on the date of data collection.

Time frame: Year 1, 2, 3

Overall Survival (OS)

OS was defined as the duration from initiation of Bosutinib therapy to date of death (all causes combined). For participants who were alive or lost to follow-up (LTFU), overall survival was censored on the date of data collection or date LTFU, respectively.

Time frame: From baseline up to 1 Year, baseline up to Year 2, baseline up to Year 3

Percentage of Participants With Disease Progression

Progression was defined as change from CP-CML to AP-CML or to BC-CML. CP-CML is frequently asymptomatic and diagnosed with \<10% blasts. Based on the ELN 2013 definition: AP-CML was defined by the presence of blast cells between 15-29% or blast cells plus promyelocytes \>30%, with blasts \<30% in blood or bone marrow, platelet count \<100\*10\^9 or clonal chromosome abnormalities in Ph+ cells. BC-CML was defined as blasts in blood or bone marrow \>=30%, extramedullary blast proliferation (excluding spleen), large foci or clusters of blasts in bone marrow biopsy.

Time frame: Year 1, 2, 3

Percentage of Participants With Permanent Discontinuation From Bosutinib Therapy

Time frame: Baseline up to 5.5 years

Cross-Intolerance Between Bosutinib and Previous Therapy

Cross-intolerance was defined as percentage of participants who permanently discontinued bosutinib due to an adverse event which also resulted in discontinuation of a previous treatment (imatinib, dasatinib, nilotinib).

Time frame: Baseline up to 5.5 years

Mean Dose of Bosutinib at Initiation of Treatment

Time frame: Baseline up to 5.5 years

Relative Bosutinib Dose Intensity

Relative dose intensity was defined as the percentage of daily dose received over the expected daily dose of the study drug.

Time frame: Baseline up to 5.5 years

Duration of Bosutinib Therapy

The duration from initiation of Bosutinib therapy up to the end of Bosutinib therapy was reported in this outcome measure.

Time frame: Baseline up to 5.5 years